International “Hemangioma Market” Overview 2018 | with USD 294.8 Million during Period 2018-2023 | Stages, Symptoms, Causes, Diagnosis, Treatment and Life Expectancy |

Fri Apr 13, 2018 - 11:15pm UTC

Global Hemangioma Market information, by type (Capillary hemangioma, Cavernous hemangioma, Compound hemangioma, Lobular capillary hemangioma (pyogenic granuloma), and others), by diagnosis (Ultrasound, MRI, CT scan, and others), by Treatment (medical therapies, laser therapy, surgery) – Forecast to 2023

Pune, India – April 13, 2018

The report titled “Hemangioma Market-Forecast to 2023″ intends to provide in-depth analysis resulting from both quantitative and qualitative analysis by Market Research Future. It includes research targeted at prospective growth opportunities alongside with present market scenarios. The report takes a holistic view of the market, imbibing the client’s point of view thereby making it a valuable guide in the quest to reap the huge market opportunities. adds “Hemangioma Market – 2018 Global Analysis, Growth, Trends and Opportunities Research Report forecasting to 2023” reports to its database.

Browse Complete 68 Pages Premium Report Enabled with Respective Tables and Figures is Available: .

Hemangioma Market – Overview:
The hemangioma market is growing mainly due to the rising cases of hemangioma. According to a recent study report published by the Market Research Future, The hemangioma market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).

Hemangioma is the birthmark or benign tumors of infancy that occurs due to an abnormal collection of blood vessels. This occurs in 5-10% of infants worldwide. Hepatic hemangiomas are mesenchymal, and usually are solitary. Hemangioma affect internal organs such as the liver, other parts of the gastrointestinal system, the brain, or organs of the respiratory system. The treatment options of hemangiomas include corticosteroid medication, beta-blockers, laser treatment, medicated gel, and surgery.

Hepatic hemangiomas are more common in females than males, and they can be seen in any age group, but mostly diagnosed in between the age of 30 to 50 years i.e. 60 % to 80%.

Notably, rising prevalence of hemangioma, and other related complications, and rising healthcare expenditure in developed countries are the key drivers promoting the growth of the market. According to a report suggested by the U.S. Centers for Medicare & Medicaid Services, in the year 2016, the U.S. health care expenditure had increased by 4.3% i.e., USD 3.3 trillion, and USD 10,348 per person. Out of this amount, 32% share was of hospital care, 20% for physician and clinical services, 10% for prescription drugs, 3% for other professional services, 4% for dental services, 2% for durable medical equipment, and others.

The great economic development has also been observed in Asia Pacific region. According to the Australian Institute of Health and Welfare, during 2015–16, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.

Other push factors such as, rising research funding, growing rates of early detection and awareness, and reimbursements and growing health insurance are also fuelling the growth of the market.

You can get access to sample report here: .

Despite these drivers, poor efficacy, cure rates and side effects of present treatment, and high cost of laser treatment are expected to decline the market growth. High cost of the laser systems is followed by high procedural cost. According to the American Society of Plastic Surgeons in 2016, the estimated physician fee for laser skin resurfacing is about USD 3,361.

Hemangioma Market – Competitive Analysis:
Angiodynamics, Inc. (U.S.), Biolase Inc. (U.S.), Valeant (Canada), IRIDEX Corp. (U.S.), Cutera (U.S.), Coherent, Inc. (U.S.), Alma Lasers (Israel), Allergan Plc (Ireland), Bayer (Germany), Akrimax Pharmaceuticals, LLC. (US), AstraZeneca (UK), Cutting Edge Laser Technologies (US), Linline Medical Systems (France), Novartis AG (Switzerland), Pfizer Inc. (US), Pierre Fabre (France) Quanta System S.p.A. (Italy), are some of the prominent players at the forefront of competition in the hemangioma market and are profiled in MRFR Analysis.

The hemangioma market is currently dominated by various players. Hemangioma are the most common benign mesenchymal tumors of the liver. They are lined by endothelial cells with a thin fibrous stroma. Owing to the rising cases of hemangioma various existing and new marketers are continuously coming up with innovative products to control this condition. For instance, Pierre Fabre S.A., a France based company, designs, develops, produces, and markets pharmaceutical products for customers in France and internationally. The company offer drugs for various treatment fields, such as diabetes, cardiology, urology, gynecology, neuropsychitry, pneumo-allergology, and rheumatology, as well as dermatology, and onco-hematology/oncology to health care professionals and their patients. On March 17, 2014, Pierre Fabre Pharmaceuticals, Inc. received FDA approval for hemangeol (propranolol hydrochloride) oral solution for the treatment of infantile hemangiomas requiring systemic therapy.

Pfizer is another US based renowned bio pharmaceutical organization. In July 2016, Pfizer and Western Oncolytics announce immuno-oncology research collaboration. This collaboration has the aim to investigate novel oncolytic virus technology. Under terms of agreement, Pfizer and Western Oncolytics will collaborate on preclinical, clinical development of WO-12 through Phase I trials. Financial terms of agreement are not disclosed.

Any query or specific requirement? Ask to our industry expert, please click: .

Valeant is another multinational, specialty pharmaceutical and medical device company. Valeant develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices which are marketed directly or indirectly in more than 100 countries. In 2015, The Company acquired Amoun, one of the largest domestic company in the Egyptian pharmaceutical market.

What makes our report unique?
1) An extensive research study on the Global Hemangioma market, and its entire ecosystem, describes the market trends, drivers, restraints and opportunities of the Hemangioma market.

2) We provide you the longest possible market segmentation based on type of products, procedures and geography and describe the market share region wise.

3) The report gives a bird eyes view on the competitive landscape which includes mergers and acquisitions, collaborations, market strategies, and new product launches.


Feel free to get in touch for discounts and customized details: .

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Info:
Name: Market Research Future
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: +1 646 845 9312

This content is produced independently of Reuters Editorial News. For content inquiry, please contact

This news is published on Reuters.

VCNN is your primary source for all venture capital news. We provide the latest breaking news and insider stories straight from the venture capital scene. Contact us at: